Order Synvisc® One Online for Clinics

Synvisc® One is a sterile, single-dose hylan G-F 20 injection supplied in a 6 mL prefilled syringe for intra-articular administration in the knee. Licensed clinics and healthcare professionals can order Synvisc One online for procedure-room use, inventory planning, and single-visit viscosupplementation workflows. The prefilled format supports consistent handling, clear documentation, and efficient scheduling for established knee osteoarthritis protocols.

Med Wholesale Supplies serves professional accounts that need authentic, brand-name medical products sourced through vetted distributors and verified supply channels. This Synvisc One clinic supply is supported by US distribution and practical logistics for orthopedic, rheumatology, sports medicine, and PM&R services.

Synvisc One Price, Unit Details, and Clinic Purchasing

Synvisc One price can vary by account status, purchase volume, distributor supply, and the quantity your clinic needs for upcoming procedure blocks. Sign in to view current account pricing and plan replenishment around scheduled knee injection visits. For multi-location organizations, unit-based purchasing can help standardize stock counts and reduce last-minute substitutions.

The supplied presentation is a Synvisc One 6ml prefilled syringe. The current product title identifies the concentration as 8 mg/mL and the unit as one 6 mL prefilled syringe. This matters operationally because the single-syringe format removes vial draw-up, reduces preparation steps, and helps staff document the exact device used in the medical record.

Clinics evaluating Synvisc One cost should consider more than acquisition price. A single-injection course can consolidate scheduling, consent, sterile setup, administration, and follow-up instructions into one encounter. That workflow difference may be relevant when comparing single-visit products with three-injection series in the same viscosupplementation category.

What Synvisc One Is and How It Works

Synvisc® One is a viscosupplement. In clinical practice, that means it is used to supplement the lubricating and shock-absorbing properties of synovial fluid in the knee joint. Its active material, hylan G-F 20, is a hyaluronic acid derivative designed for intra-articular injection by trained healthcare professionals.

According to manufacturer prescribing information, Synvisc-One is indicated for the treatment of pain in osteoarthritis of the knee in patients who have not responded adequately to conservative nonpharmacologic therapy and simple analgesics. It is not a general pain injection for every joint complaint. Clinics should align use with the labeled indication, local protocol, professional training, and patient-specific assessment.

The product is administered directly into the knee joint space. Aseptic technique, appropriate patient selection, and correct injection placement are central to safe use. For broader category context and adjacent HA products, browse our orthopedic injections.

Professional Applications in Knee Osteoarthritis Care

Orthopedic, rheumatology, sports medicine, and physical medicine practices commonly incorporate hylan G-F 20 injection products into knee osteoarthritis pathways. Synvisc One injection can be useful when a clinic wants a single-visit HA option rather than a multi-appointment series. That can simplify procedure calendars, reduce rescheduling pressure, and support consistent post-procedure counseling.

Clinical teams may coordinate Synvisc One knee injection visits with imaging review, bracing discussions, therapy planning, or other conservative care measures. The product should be administered only by healthcare professionals adequately trained in intra-articular injections. Internal protocols should cover patient identification, site confirmation, sterile preparation, lot capture, post-visit instructions, and escalation steps for adverse reactions.

For teams deciding between the one-syringe presentation and the three-syringe course in the same family, our comparison of Synvisc and Synvisc One explains practical differences that can affect scheduling and inventory.

Key Features for Clinic Inventory

• Single-injection course: supports one-visit scheduling for eligible knee osteoarthritis patients.
• Prefilled syringe: reduces preparation steps and eliminates vial draw-up.
• 6 mL fill volume: matches the labeled Synvisc One 6ml presentation.
• 8 mg/mL concentration: reflected in the current product title and ordering details.
• Sterile, single-use unit: intended for professional intra-articular administration.
• Hylan G-F 20 formulation: a high-viscosity hyaluronic acid derivative used in viscosupplementation.
• Clear lot and expiration labeling: supports traceability, inventory logs, and EMR documentation.
• SKU: 81517 for internal ordering and replenishment reference.

Quick tip: Match reorder quantities to procedure calendars rather than only to historical monthly usage.

Composition, Presentation, and Documentation

Synvisc One is supplied as a sterile aqueous preparation containing hylan G-F 20. Hylan G-F 20 is made of hylan A and hylan B polymers, which are derivatives of hyaluronan. The manufacturer describes Synvisc-One as a single 6 mL injection for intra-articular use in the knee.

From an operations perspective, the prefilled syringe supports standardized treatment-room setup. Staff can prepare the sterile field, confirm the product and expiration, record the lot number, and document the administered unit without managing a vial-to-syringe transfer. This can help reduce variability across providers and locations.

Ordering, Logistics, and Supply Planning

Professional accounts can order Synvisc One for clinics and align quantities with upcoming injection schedules. Account access allows purchasing teams to view current Synvisc One price information, manage reorders, and plan supply around provider availability. For practices with mixed musculoskeletal services, the rheumatology category can help organize adjacent professional-use products.

We support temperature-controlled handling when required and tracked US delivery. Shipment planning should account for clinic receiving hours, storage procedures, and documentation practices. Receiving staff should inspect outer packaging, confirm the correct product, record lot and expiration information, and route the syringe according to your facility’s handling process.

Supply can vary by lot and distributor. If a clinically acceptable substitute is needed, confirm protocol differences before switching. Single-visit products, three-visit series, syringe volumes, and product-specific instructions are not interchangeable from a workflow standpoint, even when they belong to the broader HA injection category.

Safety, Side Effects, and Precautions

Synvisc One should be used according to the product labeling and professional judgment. Manufacturer information lists local reactions such as pain, swelling, heat, redness, and fluid buildup around the injected knee as possible adverse events. Clinics commonly counsel patients to report severe pain, significant swelling, signs of infection, or symptoms that worsen after the visit.

Contraindications and precautions should be reviewed before administration. The product should not be injected into a knee with infection or skin disease in the injection area. It should not be administered intravascularly, extra-articularly, or into synovial tissue or the capsule. Patient allergy history, current joint status, and recent procedures should be part of the pre-injection assessment.

Post-procedure instructions often include limiting strenuous activity for a short period after a knee gel injection, based on clinician direction and the facility’s protocol. Avoid turning these instructions into a fixed universal rule because activity guidance can vary by patient condition, injection technique, and the provider’s assessment. Document the counseling given and the contact pathway for concerning symptoms.

Expected Response and Follow-Up Planning

Response to Synvisc One injection is individualized. Manufacturer materials describe Synvisc-One as a treatment for osteoarthritis knee pain, but clinical results can differ by disease severity, activity level, comorbidities, and the broader care plan. The product should not be presented as guaranteed relief or as a replacement for assessment, rehabilitation planning, weight management guidance, bracing decisions, or other clinician-directed measures.

Many clinics schedule follow-up based on protocol, patient symptoms, and provider preference. Staff should document baseline symptoms, the injected knee, product identifiers, immediate tolerance, and aftercare instructions. For teams comparing duration expectations across HA products, the article on Synvisc One and Durolane provides useful product-selection context.

When patients ask whether Synvisc One works, an answer-first approach helps: it is a labeled option for knee osteoarthritis pain in appropriate patients, but benefit is not the same for everyone. Clinics should communicate realistic expectations, identify follow-up triggers, and avoid unsupported claims about response rates or duration for a specific patient.

Comparable Products and Protocol Choices

Synvisc One is often compared with multi-injection HA regimens and other single-injection products. The closest product-family alternative is Synvisc Classic 3 x 2 mL, which supports a three-visit approach rather than a single 6 mL syringe. The choice can affect chair time, scheduling cadence, patient counseling, and reorder quantities.

Other clinic-supplied HA options include Durolane 3 mL and Monovisc 4 mL. Product selection should account for labeled instructions, provider familiarity, clinic protocol, patient history, and supply planning. Similar class names do not mean identical dosing schedules or syringe characteristics.

For broader evaluation, see our article on Monovisc and Synvisc differences. Practices that stock multiple viscosupplements may also use a brand-level view for Synvisc products when standardizing procurement across providers.

Storage, Handling, and Treatment-Room Workflow

Follow the manufacturer’s package insert for storage, handling, preparation, and administration requirements. Clinics should keep the outer carton and instructions available for staff reference, especially when onboarding new providers or rotating procedure-room personnel. Lot number and expiration capture should be part of routine documentation before administration.

The prefilled syringe design can simplify setup, but it does not replace sterile technique. Staff should avoid using damaged packaging, expired units, or syringes that do not match the intended product. Internal checklists can help confirm patient identity, affected knee, consent, product name, syringe volume, expiration, lot number, and post-visit guidance.

Why it matters: A consistent receiving and documentation process helps protect both clinical quality and inventory accuracy.

Authoritative Sources

• Manufacturer product information
• SYNVISC ONE® prescribing information

Ready to add this single-dose HA option to your workflow? Sign in to view current account pricing, confirm the 6 mL prefilled syringe presentation, and schedule replenishment for upcoming clinic use.

This content is for informational purposes only and is not a substitute for professional medical advice.